Market Insight - ThromboGenics: a biotech tale of four cities
This article was originally published in Scrip
Executive Summary
Rare is the biotech firm founded on a multi-million euro royalty stream. Gerhard Symons relates the unusual story of a Belgian company with a flair for European dealmaking